The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Dose adjustments are commonplace in the treatment of multiple myeloma (MM), particularly in the older and frail population who are less able to tolerate toxicities. Clinical trial data from the OPTIMISMM trial (NCT01734928) provided evidence for the use of pomalidomide, bortezomib, and dexamethasone (PVd) in the treatment of relapsed/refractory MM. However, there is a lack of understanding of the outcomes of this combination in patients who are frail or require a dose adjustment.1
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on results from the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
The Multiple Myeloma Hub has previously covered the overall results from OPTIMISMM here.
Figure 1. Response data by frailty status and bortezomib dose adjustment*
CI, confidence interval; CR, complete response; NE, not evaluable; OR, odds ratio; ORR, overall response date; PD, progressive disease; PR, partial response; sCR, stringent CR; SD, stable disease; VGPR, very good PR.
*Data from Oriol, et al.1
Key learnings1 |
---|
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content